Literature DB >> 18054101

HDR prostate monotherapy: dosimetric effects of implant deformation due to posture change between TRUS- and CT-imaging.

Yvette Seppenwoolde1, Inger-Karine Kolkman-Deurloo, Dick Sipkema, Mark de Langen, John Praag, Peter Jansen, Ben Heijmen.   

Abstract

HDR monotherapy for prostate cancer consists of four fractions. The first fraction is delivered with online TRUS-based treatment planning. For the last three fractions the treatment plan is based on a CT-scan acquired in between fractions 1 and 2. The patient position (high lithotomy, rectal US probe) during TRUS-guided catheter implantation and first fraction differs from the patient position in the CT-scan and the remaining three fractions (lowered legs, no TRUS probe). This study describes the effect of posture changes on dose distributions when a plan designed for the TRUS anatomy is applied to the CT-scan anatomy. The aim is to quantify dosimetrical errors that would result from skipping the use of a planning CT-scan, and rely for all fractions on the TRUS plan. Such a procedure would substantially reduce the involved workload, and would increase patient comfort. For three prostate cancer patients, images were acquired during TRUS-guided catheter implantation. Furthermore, a CT-scan (no US probe in rectum, different position of legs) was acquired and matched with the TRUS set. On both TRUS and CT, prostate, urethra and rectum were delineated and all catheters were traced. For each patient, an optimized treatment plan was designed using TRUS images and contours. Catheters with obtained dwell positions of the TRUS plan were transferred individually to the catheter positions in the CT. Changes in dose distribution due to relocation of catheters were evaluated using DVHs. For all patients the dose distributions changed significantly due to rearrangement of the catheters, having most impact on the urethra (maximum observed change: 32% volume receiving > or = 120% of the prescribed dose) and a reduction of PTV coverage (6-28%). Implant deformation when changing from TRUS patient set-up to CT set-up affected negatively the quality of optimized treatment plans. Inclusion of more patients in this study was planned, but because of the observed strong negative effects it is already concluded that the TRUS plan cannot be used for the last three fractions with a deviating patient set-up.

Entities:  

Mesh:

Year:  2007        PMID: 18054101     DOI: 10.1016/j.radonc.2007.11.004

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  10 in total

Review 1.  In vivo dosimetry: trends and prospects for brachytherapy.

Authors:  G Kertzscher; A Rosenfeld; S Beddar; K Tanderup; J E Cygler
Journal:  Br J Radiol       Date:  2014-07-08       Impact factor: 3.039

2.  Intraoperative 360-deg three-dimensional transvaginal ultrasound during needle insertions for high-dose-rate transperineal interstitial gynecologic brachytherapy of vaginal tumors.

Authors:  Jessica Robin Rodgers; Jeffrey Bax; Kathleen Surry; Vikram Velker; Eric Leung; David D'Souza; Aaron Fenster
Journal:  J Med Imaging (Bellingham)       Date:  2019-04-08

3.  Comparison of prostate contours between conventional stepping transverse imaging and Twister-based sagittal imaging in permanent interstitial prostate brachytherapy.

Authors:  Shogo Kawakami; Hiromichi Ishiyama; Takefumi Satoh; Hideyasu Tsumura; Akane Sekiguchi; Kouji Takenaka; Ken-Ichi Tabata; Masatsugu Iwamura; Kazushige Hayakawa
Journal:  J Contemp Brachytherapy       Date:  2017-08-30

4.  Use of deformable image registration techniques to estimate dose to organs at risk following prostate external beam radiation therapy and high-dose-rate brachytherapy.

Authors:  Marie Vozzo; Joel Poder; Johnson Yuen; Joseph Bucci; Annette Haworth
Journal:  J Contemp Brachytherapy       Date:  2021-02-18

5.  Axially rigid steerable needle with compliant active tip control.

Authors:  M de Vries; J Sikorski; S Misra; J J van den Dobbelsteen
Journal:  PLoS One       Date:  2021-12-16       Impact factor: 3.240

6.  Advantages of TRUS-based delineation for high-dose-rate prostate brachytherapy planning.

Authors:  Heloise Lavoie-Gagnon; Andre-Guy Martin; Eric Poulin; Louis Archambault; Laurie Pilote; William Foster; Eric Vigneault; Damien Carignan; Frederic Lacroix
Journal:  J Contemp Brachytherapy       Date:  2022-02-18

7.  Low-dose-rate or high-dose-rate brachytherapy in treatment of prostate cancer - between options.

Authors:  Janusz Skowronek
Journal:  J Contemp Brachytherapy       Date:  2013-03-29

Review 8.  Brachytherapy in the therapy of prostate cancer - an interesting choice.

Authors:  Janusz Skowronek
Journal:  Contemp Oncol (Pozn)       Date:  2013-11-14

9.  Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer.

Authors:  Pirus Ghadjar; Sebastian L Oesch; Cyrill A Rentsch; Bernhard Isaak; Nikola Cihoric; Peter Manser; George N Thalmann; Daniel M Aebersold
Journal:  Radiat Oncol       Date:  2014-05-28       Impact factor: 3.481

10.  A cold spot compensation technique using a combination of trans-rectal ultrasonography and intraoperative computed tomography for interstitial permanent prostate brachytherapy: a single-arm prospective trial.

Authors:  Hiromichi Ishiyama; Hideyasu Tsumura; Shogo Kawakami; Takefumi Satoh; Akane Sekiguchi; Ken-Ichi Tabata; Masatsugu Iwamura; Kazushige Hayakawa
Journal:  J Contemp Brachytherapy       Date:  2018-02-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.